Reducing donor antibodies for stem cell transplant patients
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests whether adding dexamethasone, intravenous immunoglobulin, and extra donor cells can lower donor-specific antibodies in people receiving half-matched stem cell transplants. The goal is to help more patients safely get a transplant when fully matched donors aren't available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer or blood disorder, like leukemia, lymphoma, severe anemia, or myelodysplastic syndrome, and need a stem cell transplant.
- You are between 18 and 65 years old.
- You weigh between 88 and 220 pounds (40 to 100 kg).
- You have donor-specific antibodies above a certain level (MFI > 500) that could make a half-matched transplant risky.
- No fully matched related or unrelated donor without these antibodies is available for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an immune-suppressing treatment for people with sickle cell disease or beta-thalassemia who are preparing for a stem cell transplant from a donor. It aims to help the transplant work better by changing the immune response.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This trial tests a special treatment to lower high levels of anti-HLA antibodies before a stem cell transplant. The goal is to help the transplant succeed and reduce the risk of rejection.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.